{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:14:03Z","timestamp":1784542443976,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although a considerable volume of data supporting induction or aggravation of psoriasis because of angiotensin-converting enzyme (ACE) inhibitor use exists, it remains insufficient for definitive conclusions. Therefore, we aimed to evaluate the association between ACE inhibitor use and psoriasis incidence through a systematic literature review and meta-analysis. We searched for qualifying studies across PubMed, Web of Science, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between ACE inhibitor use and psoriasis incidence. Eight studies with a total of 54,509 patients with a psoriasis diagnosis were included in this meta-analysis. The pooled OR for psoriasis incidence among ACE inhibitor users was 1.52 (95% CI, 1.16\u20132.00) compared to that among non-users. From subgroup analysis by continent, the OR for ACE inhibitor users versus non-users was 2.37 (95% CI 1.28\u20134.37) in Asia. Per the subgroup analysis by climate, the OR for ACE inhibitor users vs non-users in dry climate was 3.45 (95% CI: 2.05\u20135.79) vs 1.32 (95% CI 1.01\u20131.73) in temperate climate. Our results reveal a significant association between ACE inhibitor use and psoriasis incidence.<\/jats:p>","DOI":"10.1038\/s41598-021-89490-z","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T10:09:20Z","timestamp":1620727760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence"],"prefix":"10.1038","volume":"11","author":[{"given":"Gonjin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yea","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Young","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"89490_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000073106","volume":"207","author":"PG Stavropoulos","year":"2003","unstructured":"Stavropoulos, P. G., Kostakis, P. G., Papakonstantinou, A. M., Panagiotopoulos, A. & Petridis, A. D. Coexistence of psoriasis and pemphigus after enalapril intake. Dermatology 207, 336\u2013337 (2003).","journal-title":"Dermatology"},{"key":"89490_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1751-7176.2011.00508.x","volume":"13","author":"JL Izzo Jr","year":"2011","unstructured":"Izzo, J. L. Jr. & Weir, M. R. Angiotensin-converting enzyme inhibitors. J. Clin. Hypertens. (Greenwich). 13, 667\u2013675 (2011).","journal-title":"J. Clin. Hypertens. (Greenwich)."},{"key":"89490_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MJT.0b013e31818f9e99","volume":"17","author":"P Thakor","year":"2010","unstructured":"Thakor, P. et al. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am. J. Ther. 17, 92\u201395 (2010).","journal-title":"Am. J. Ther."},{"key":"89490_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000247861","volume":"181","author":"R Wolf","year":"1990","unstructured":"Wolf, R., Tamir, A. & Brenner, S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 181, 51\u201353 (1990).","journal-title":"Dermatologica"},{"key":"89490_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0190-9622(08)81761-6","volume":"28","author":"P Gilleaudeau","year":"1993","unstructured":"Gilleaudeau, P., Vallat, V. P., Carter, D. M. & Gottlieb, A. B. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J. Am. Acad. Dermatol. 28, 490\u2013492 (1993).","journal-title":"J. Am. Acad. Dermatol."},{"key":"89490_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1136\/bmj.295.6609.1352","volume":"295","author":"NW Hamlet","year":"1987","unstructured":"Hamlet, N. W., Keefe, M. & Kerr, R. E. Does captopril exacerbate psoriasis?. Br. Med. J. Clin. Res. Ed. 295, 1352 (1987).","journal-title":"Br. Med. J. Clin. Res. Ed."},{"key":"89490_CR7","first-page":"274","volume":"37","author":"TT Hauschild","year":"1986","unstructured":"Hauschild, T. T., Bauer, R. & Kreysel, H. W. Erstmanifestation einer eruptiv-exanthematischen Psoriasis vulgaris unter Captoprilmedikation [Initial manifestation of eruptive exanthematous psoriasis vulgaris caused by captopril medication]. Hautarzt 37, 274\u2013277 (1986).","journal-title":"Hautarzt"},{"key":"89490_CR8","first-page":"162","volume":"40","author":"R Wolf","year":"1987","unstructured":"Wolf, R., Dorfman, B. & Krakowski, A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis 40, 162\u2013164 (1987).","journal-title":"Cutis"},{"key":"89490_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1540-9740.2006.04515.x","volume":"5","author":"D Antono","year":"2006","unstructured":"Antono, D., Grozdev, I., Pehlivanov, G. & Tsankov, N. Psoriatic erythroderma associated with enalapril. Skinmed 5, 90\u201392 (2006).","journal-title":"Skinmed"},{"key":"89490_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","volume":"1","author":"N Tsankov","year":"2000","unstructured":"Tsankov, N., Angelova, I. & Kazandjieva, J. Drug-induced psoriasis. Recognition and management. Am. J. Clin. Dermatol. 1, 159\u2013165 (2000).","journal-title":"Am. J. Clin. Dermatol."},{"key":"89490_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/00015550510032823","volume":"85","author":"AD Cohen","year":"2005","unstructured":"Cohen, A. D. et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta. Derm. Venereol. 85, 299\u2013303 (2005).","journal-title":"Acta. Derm. Venereol."},{"key":"89490_CR12","first-page":"1116","volume":"159","author":"S Gerdes","year":"2008","unstructured":"Gerdes, S., Zahl, V. A., Knopf, H., Weichenthal, M. & Mrowietz, U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br. J. Dermatol. 159, 1116\u20131123 (2008).","journal-title":"Br. J. Dermatol."},{"key":"89490_CR13","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","volume":"158","author":"YB Brauchli","year":"2008","unstructured":"Brauchli, Y. B., Jick, S. S., Curtin, F. & Meier, C. R. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br. J. Dermatol. 158, 1299\u20131307 (2008).","journal-title":"Br. J. Dermatol."},{"key":"89490_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1346-8138.2009.00777.x","volume":"37","author":"N Al-Mutairi","year":"2010","unstructured":"Al-Mutairi, N., Al-Farag, S., Al-Mutairi, A. & Al-Shiltawy, M. Comorbidities associated with psoriasis: an experience from the Middle East. J. Dermatol. 37, 146\u2013155 (2010).","journal-title":"J. Dermatol."},{"key":"89490_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","volume":"150","author":"S Wu","year":"2014","unstructured":"Wu, S., Han, J., Li, W. Q. & Qureshi, A. A. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 150, 957\u2013963 (2014).","journal-title":"JAMA Dermatol."},{"key":"89490_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pcd.2016.07.002","volume":"11","author":"L Jacob","year":"2017","unstructured":"Jacob, L. & Kostev, K. Psoriasis risk in patients with type 2 diabetes in German primary care practices. Prim. Care. Diabetes. 11, 52\u201356 (2017).","journal-title":"Prim. Care. Diabetes."},{"key":"89490_CR17","doi-asserted-by":"publisher","first-page":"e0202854","DOI":"10.1371\/journal.pone.0202854","volume":"13","author":"HN Kim","year":"2018","unstructured":"Kim, H. N., Han, K., Song, S. W. & Lee, J. H. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study. PLoS ONE 13, e0202854 (2018).","journal-title":"PLoS ONE"},{"key":"89490_CR18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S175244","volume":"14","author":"JM Liu","year":"2018","unstructured":"Liu, J. M., Lin, C. Y., Chuang, H. C. & Hsu, R. J. No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study. Ther. Clin. Risk Manag. 14, 1831\u20131837 (2018).","journal-title":"Ther. Clin. Risk Manag."},{"key":"89490_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","volume":"577","author":"C Ceconi","year":"2007","unstructured":"Ceconi, C. et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 577, 1\u20136 (2007).","journal-title":"Eur. J. Pharmacol."},{"key":"89490_CR20","first-page":"3335","volume":"157","author":"JG Eriksen","year":"1995","unstructured":"Eriksen, J. G., Christiansen, J. J. & Asmussen, I. Pustulosis palmoplantaris udl\u00f8st af angiotensinkonverterende enzymhaemmere [Postulosis palmoplantaris caused by angiotensin-converting enzyme inhibitors]. Ugeskr. Laeger. 157, 3335\u20133336 (1995).","journal-title":"Ugeskr. Laeger."},{"key":"89490_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1515\/hsz-2012-0348","volume":"394","author":"KM Gauthier","year":"2013","unstructured":"Gauthier, K. M., Cepura, C. J. & Campbell, W. B. ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries. Biol. Chem. 394, 1205\u20131212 (2013).","journal-title":"Biol. Chem."},{"key":"89490_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","volume":"16","author":"S Taddei","year":"2016","unstructured":"Taddei, S. & Bortolotto, L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am. J. Cardiovasc. Drugs. 16, 309\u2013321 (2016).","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"89490_CR23","first-page":"77","volume":"35","author":"R Wolf","year":"1981","unstructured":"Wolf, R., Machtey, I., Feverman, E. J. & Creter, D. The kallikrein-kinin pathway in psoriasis. Preliminary observations. Biomedicine 35, 77\u201378 (1981).","journal-title":"Biomedicine"},{"key":"89490_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/emmm.201000080","volume":"2","author":"A Benigni","year":"2010","unstructured":"Benigni, A., Cassis, P. & Remuzzi, G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2, 247\u2013257 (2010).","journal-title":"EMBO Mol. Med."},{"key":"89490_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00109-013-1051-z","volume":"91","author":"RA Gonzalez-Villalobos","year":"2013","unstructured":"Gonzalez-Villalobos, R. A. et al. Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme. J. Mol. Med. (Berl) 91, 1143\u20131154 (2013).","journal-title":"J. Mol. Med. (Berl)"},{"key":"89490_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physiolgenomics.00062.2002","volume":"11","author":"DM Tham","year":"2002","unstructured":"Tham, D. M. et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genom. 11, 21\u201330 (2002).","journal-title":"Physiol. Genom."},{"key":"89490_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cei.12467","volume":"179","author":"Y Chang","year":"2015","unstructured":"Chang, Y. & Wei, W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin. Exp. Immunol. 179, 137\u2013145 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"89490_CR28","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.1038\/s41598-017-13746-w","volume":"7","author":"R Terenzi","year":"2017","unstructured":"Terenzi, R. et al. Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. Sci. Rep. 7, 13293 (2017).","journal-title":"Sci. Rep."},{"key":"89490_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0002-9149(99)80703-6","volume":"75","author":"KS Woo","year":"1995","unstructured":"Woo, K. S., Norris, R. M. & Nicholls, G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am. J. Cardiol. 75, 967\u2013968 (1995).","journal-title":"Am. J. Cardiol."},{"key":"89490_CR30","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","volume":"332","author":"SE McDowell","year":"2006","unstructured":"McDowell, S. E., Coleman, J. J. & Ferner, R. E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332, 1177\u20131181 (2006).","journal-title":"BMJ"},{"key":"89490_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0733-8635(18)30144-X","volume":"12","author":"EM Farber","year":"1994","unstructured":"Farber, E. M. & Nall, L. Psoriasis in the tropics. Epidemiologic, genetic, clinical, and therapeutic aspects. Dermatol. Clin. 12, 805\u2013816 (1994).","journal-title":"Dermatol. Clin."},{"key":"89490_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603\u2013605 (2010).","journal-title":"Eur. J. Epidemiol."},{"key":"89490_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"89490_CR34","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer. Inst. 22, 719\u2013748 (1959).","journal-title":"J. Natl. Cancer. Inst."},{"key":"89490_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials revisited. Contemp. Clin. Trials. 45, 139\u2013145 (2015).","journal-title":"Contemp. Clin. Trials."},{"key":"89490_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"},{"key":"89490_CR37","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89490-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:54:41Z","timestamp":1670054081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89490-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"17 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10037"}}